Clinical trial collaboration and supply agreement between Boehringer and BioNTech to conduct a Phase Ib/II clinical trial to explore ...

A total of 20 patients were included in the safety run-in cohort and completed preliminary evaluation. Results demonstrated that Opamtistomig in combination with chemotherapy was generally well ...

A new study co-led by the Institute for Systems Biology (ISB) shows that some lung cancers can change identity as they evolve ...

Researchers have developed a pathology tool powered by AI that can predict whether a patient with extensive-stage small cell ...

Learn how G-CSF and trilaciclib help prevent febrile neutropenia in extensive-stage SCLC, with NCCN-backed timing tips and ...

ES-SCLC patients show limited benefit from 3L therapies, highlighting the need for novel treatments to improve outcomes. SCLC is aggressive, often diagnosed at an extensive stage, and treated with ...

The therapeutic landscape of small cell lung cancer (SCLC) is undergoing a paradigm shift with the emergence of delta-like ligand-3 (DLL3)–directed therapies, particularly tarlatamab, a first-in-class ...

Is Zepzelca Right for Me? To help choose the right treatment for you, your health care provider will consider what type of lung cancer you have, the treatments you have received, and whether the ...

Committee for Medicinal Products for Human Use (CHMP) adopted positive opinions for two drugs for the treatment of adults with small cell lung cancer (SCLC). The first, Imdylltra (tarlatamab, Amgen), ...

Results of a new study conclude that a pathology tool powered by artificial intelligence can predict whether a patient with ...